A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
Latest Information Update: 18 Jun 2024
At a glance
- Drugs GLPG 5101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Atalanta-1
- Sponsors CellPoint
- 14 Jun 2024 Results (As of the data cut-off date of December 20, 2023, n=34 )published in the Galapagos NV Media Release
- 04 Apr 2024 According to a Galapagos NV Media Release, data from the study will be presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Glasgow, UK, on 14-17 April 2024.
- 15 Feb 2024 According to a Galapagos NV Media Release, data from the study will be presented at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15-17 February 2024 in Valencia, Spain.